Hanna Kim

Ms. Hanna Kim

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
BSBrian Song
Brian Song
HQHeineken Queen
Heineken Queen
SFSarah F. Ferris
Sarah F. Ferris
RMReliza McGinnis
Reliza McGinnis
CKChaitanya Karanam
Chaitanya Karanam
AGAnutosh Ganguly
Anutosh Ganguly
Histotripsy-focused ultrasound treatment gives rise to systemic antitumor immune responses. We investigated whether histotripsy effects on immunosuppressive tumor hypoxia were a potential mechanism for these immunostimulatory effects. Immunocompetent or CD8-deficient C57BL/6 mice with flank B16F10 or YUMM1.7 melanoma tumors underwent sham or subtotal histotripsy. Tumor growth, immune cell infiltration, and intratumoral hypoxia responses were examined using flow cytometry and fluorescence microscopy. Chemokine receptor CXCR3 and hypoxia-inducible factor-1α (HIF1α) were intercepted with antibodies and inhibitors to assess their roles in immune responses after histotripsy. Histotripsy-treated tumors exhibited rapid loss of intratumoral hypoxia and suppression of HIF1α and downstream prosurvival proteins. Histotripsy was followed by intratumoral upregulation of the CXCR3 ligand CXCL10 and CXCR3+/CD8+ T-cell infiltration. Tumor growth inhibition by histotripsy was significantly diminished in CD8-deficient mice and mice receiving anti-CXCR3 mAb. Post-histotripsy inhibition of hypoxia and tumor growth eventually receded in parallel with cessation of CD8+ T-cell influx, and pharmacologic HIF1α suppression with the MEK inhibitor trametinib substantially augmented the therapeutic effects of histotripsy. Transient abrogation of intratumoral hypoxia and HIF1α-associated hypoxia responses is mechanistically linked with intratumoral infiltration of activated CXCR3+/CD8+ T cells via CXCL10–CXCR3 engagement. These findings suggest that the immune effects of histotripsy may be regulated by hypoxia abrogation and that pharmacologic hypoxia abrogation could potentiate the immunotherapeutic effects of histotripsy.

26 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RMReliza McGinnis
Reliza McGinnis
BSBrian Song
Brian Song
HKHanna Kim
Hanna Kim
ALAnna Lorenzon
Anna Lorenzon
Jiaqi ShiJiaqi Shi
Jiaqi Shi
ZXZhen Xu
Zhen Xu
Background/Objectives: Preclinical animal studies and clinical case reports have shown evidence of histotripsy being capable of inducing anti-tumor immune responses strong enough to inhibit tumor growth of off-target tumors. Previous studies exploring histotripsy immune stimulation have used a single therapy dose. This study aims to explore how histotripsy dose affects local tumor immune stimulation in a murine melanoma model. Methods: C57BL/6J mice bearing subcutaneous B16F10 tumors were treated with histotripsy using an ultrasound-guided 8-element 1 MHz transducer operating at a 100 Hz pulse repetition frequency (PRF) and >30 MPa peak-negative pressure. The histotripsy dose was defined by the number of pulses (8, 20, 40, or 100) per focal location (ppl). Tissue damage and residual tissue structure were measured histologically and scored by a trained pathologist. The longitudinal effect of histotripsy dosing was assessed using tumor growth and survival. Acute immune stimulation was measured at days 2 and 7 post-treatment via immunofluorescence staining of the treated tumor. Results: Histotripsy doses at 20, 40, and 100 ppl achieved significant tumor necrosis within the target region (>75%), with residual structure decreasing as the dose increased. Overall, the greatest tumor control was observed in mice that received the 40 ppl dose compared to untreated mice. This correlates with the 40 ppl dose also having the largest increase in CD45+ immune cells and CD8+ T cells 7 days post-treatment compared to untreated mice. Conclusions: The effect of histotripsy dosing on immune infiltration and tumor growth highlights the significant impact of histotripsy dose on clinical effects.

2 July 2025
Verified
Other
Open access
BSBrian Song
Brian Song
HQHeineken Queen
Heineken Queen
SFSarah F. Ferris
Sarah F. Ferris
RMReliza McGinnis
Reliza McGinnis
CKChaitanya Karanam
Chaitanya Karanam
AGAnutosh Ganguly
Anutosh Ganguly
Histotripsy-focused ultrasound treatment gives rise to systemic antitumor immune responses. We investigated whether histotripsy effects on immunosuppressive tumor hypoxia were a potential mechanism for these immunostimulatory effects. Immunocompetent or CD8-deficient C57BL/6 mice with flank B16F10 or YUMM1.7 melanoma tumors underwent sham or subtotal histotripsy. Tumor growth, immune cell infiltration, and intratumoral hypoxia responses were examined using flow cytometry and fluorescence microscopy. Chemokine receptor CXCR3 and hypoxia-inducible factor-1α (HIF1α) were intercepted with antibodies and inhibitors to assess their roles in immune responses after histotripsy. Histotripsy-treated tumors exhibited rapid loss of intratumoral hypoxia and suppression of HIF1α and downstream prosurvival proteins. Histotripsy was followed by intratumoral upregulation of the CXCR3 ligand CXCL10 and CXCR3+/CD8+ T-cell infiltration. Tumor growth inhibition by histotripsy was significantly diminished in CD8-deficient mice and mice receiving anti-CXCR3 mAb. Post-histotripsy inhibition of hypoxia and tumor growth eventually receded in parallel with cessation of CD8+ T-cell influx, and pharmacologic HIF1α suppression with the MEK inhibitor trametinib substantially augmented the therapeutic effects of histotripsy. Transient abrogation of intratumoral hypoxia and HIF1α-associated hypoxia responses is mechanistically linked with intratumoral infiltration of activated CXCR3+/CD8+ T cells via CXCL10–CXCR3 engagement. These findings suggest that the immune effects of histotripsy may be regulated by hypoxia abrogation and that pharmacologic hypoxia abrogation could potentiate the immunotherapeutic effects of histotripsy.

2 July 2025
Verified
Other
Open access
PDF file
BSBrian Song
Brian Song
HQHeineken Queen
Heineken Queen
SFSarah F. Ferris
Sarah F. Ferris
RMReliza McGinnis
Reliza McGinnis
CKChaitanya Karanam
Chaitanya Karanam
AGAnutosh Ganguly
Anutosh Ganguly
Supplementary Figure S7: Flow cytometric analysis of immune cell infiltration in tumors treated with or without histotripsy or Trametinib.

2 July 2025
Verified
Other
Open access
PDF file
BSBrian Song
Brian Song
HQHeineken Queen
Heineken Queen
SFSarah F. Ferris
Sarah F. Ferris
RMReliza McGinnis
Reliza McGinnis
CKChaitanya Karanam
Chaitanya Karanam
AGAnutosh Ganguly
Anutosh Ganguly
Supplementary Figure S2: Transient HIF-1α downregulation is also observed in the YUMM1.7 melanoma cell line.

2 July 2025
Verified
Other
Open access
PDF file
BSBrian Song
Brian Song
HQHeineken Queen
Heineken Queen
SFSarah F. Ferris
Sarah F. Ferris
RMReliza McGinnis
Reliza McGinnis
CKChaitanya Karanam
Chaitanya Karanam
AGAnutosh Ganguly
Anutosh Ganguly
Supplementary Figure S1: Histotripsy causes abrogation of tumor hypoxia and subversion of HIF signaling.